(NASDAQ: NKTR) Nektar Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.16%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.22%.
Nektar Therapeutics's earnings in 2025 is -$133,041,000.On average, 6 Wall Street analysts forecast NKTR's earnings for 2025 to be -$151,033,744, with the lowest NKTR earnings forecast at -$171,464,298, and the highest NKTR earnings forecast at -$133,374,906. On average, 8 Wall Street analysts forecast NKTR's earnings for 2026 to be -$160,623,089, with the lowest NKTR earnings forecast at -$224,690,190, and the highest NKTR earnings forecast at -$124,938,168.
In 2027, NKTR is forecast to generate -$184,491,614 in earnings, with the lowest earnings forecast at -$290,323,051 and the highest earnings forecast at -$125,186,307.